Aridis Pharmaceuticals has received an undisclosed grant to develop Panaecin (gallium citrate) to treat bacterial lung infections. The grant was provided by Cystic Fibrosis Foundation Therapeutics (CFFT).
Panaecin is being evaluated in a Phase 2a clinical trial (GALLIUM-IP-13, NCT02354859) in CF patients who are chronically infected with Pseudomonas aeruginosa. The total trial period is nine weeks, and patients are being enrolled.
The treatment is designed to fight acute and chronic lung infections by destroying bacteria that enter the airways. It kills gram-negative and gram-positive bacteria, including antibiotic-resistant strains and highly antibiotic-resistant biofilms.
